European Pharmacovigilance Update Still Causing Concern
This article was originally published in The Pink Sheet Daily
The European pharma industry understands the need to tighten EU pharmacovigilance rules, but increased powers for a new advisory and assessment body could signal trouble ahead.
You may also be interested in...
The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.
NPS Pharmaceuticals, GSK, Roche and Cangene receive early holiday gifts as FDA goes on an approval spree. But EMA bears more bad news for Merck’s Tredaptive.
EMA publishes a list of active ingredients that must be monitored by European Union countries as part of efforts there to improve interstate communication and drug safety.